Benitec Biopharma (NASDAQ:BNTC - Get Free Report) had its target price raised by equities researchers at Leerink Partners from $18.00 to $18.27 in a research report issued on Monday, Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Leerink Partners's price objective would suggest a potential upside of 108.42% from the stock's current price.
Several other analysts have also recently commented on the stock. Royal Bank Of Canada raised shares of Benitec Biopharma to an "outperform" rating in a research note on Tuesday, September 15th. Wall Street Zen lowered shares of Benitec Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, September 19th. Raymond James Financial started coverage on shares of Benitec Biopharma in a research report on Friday, October 23rd. They issued an "outperform" rating and a $14.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating on shares of Benitec Biopharma in a report on Monday, November 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Benitec Biopharma in a report on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Benitec Biopharma currently has an average rating of "Moderate Buy" and a consensus target price of $21.85.
Get Our Latest Research Report on Benitec Biopharma
Benitec Biopharma Stock Performance
Shares of NASDAQ:BNTC traded down $0.27 during trading on Monday, hitting $8.77. 23,618 shares of the stock were exchanged, compared to its average volume of 148,232. The company has a market capitalization of $305.85 million, a price-to-earnings ratio of -8.63 and a beta of 0.26. Benitec Biopharma has a 1-year low of $7.89 and a 1-year high of $14.39. The company's fifty day simple moving average is $9.67 and its 200-day simple moving average is $11.39.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Friday, November 13th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. On average, research analysts forecast that Benitec Biopharma will post -1.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Benitec Biopharma
Several institutional investors have recently modified their holdings of BNTC. Nantahala Capital Management LLC boosted its holdings in Benitec Biopharma by 12.7% during the third quarter. Nantahala Capital Management LLC now owns 1,677,567 shares of the biotechnology company's stock worth $16,776,000 after purchasing an additional 189,196 shares during the last quarter. AWM Investment Company Inc. bought a new position in Benitec Biopharma in the second quarter valued at $2,515,000. Bank of New York Mellon Corp bought a new position in Benitec Biopharma in the second quarter valued at $804,000. ADAR1 Capital Management LLC bought a new position in Benitec Biopharma in the first quarter valued at $186,000. Finally, Bank of America Corp DE increased its stake in Benitec Biopharma by 43.3% in the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company's stock valued at $185,000 after buying an additional 5,251 shares during the last quarter. Institutional investors own 52.19% of the company's stock.
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company's lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.